[go: up one dir, main page]

WO2003061557A3 - Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees - Google Patents

Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees Download PDF

Info

Publication number
WO2003061557A3
WO2003061557A3 PCT/US2002/025854 US0225854W WO03061557A3 WO 2003061557 A3 WO2003061557 A3 WO 2003061557A3 US 0225854 W US0225854 W US 0225854W WO 03061557 A3 WO03061557 A3 WO 03061557A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
making
pharmaceutical compositions
administration
compositions
Prior art date
Application number
PCT/US2002/025854
Other languages
English (en)
Other versions
WO2003061557A2 (fr
Inventor
Andrew G Franz
Elaine A Strauss
Phillip A Dimenna
Rocco L Gemma
Original Assignee
King Pharmaceuticals Inc
Andrew G Franz
Elaine A Strauss
Phillip A Dimenna
Rocco L Gemma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc, Andrew G Franz, Elaine A Strauss, Phillip A Dimenna, Rocco L Gemma filed Critical King Pharmaceuticals Inc
Priority to AU2002341555A priority Critical patent/AU2002341555A1/en
Publication of WO2003061557A2 publication Critical patent/WO2003061557A2/fr
Publication of WO2003061557A3 publication Critical patent/WO2003061557A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne en général des compositions pharmaceutiques stables, ainsi que des méthodes de fabrication et d'administration desdites compositions. Dans un aspect, l'invention concerne des compositions pharmaceutiques stabilisées contenant des ingrédients pharmaceutiquement actifs, tels que la lévothyroxine sodique (T4) et la liothyronine sodique (T3) (médicaments à base d'hormones thyroïdiennes), de préférence sous forme de doses solides à libération immédiate. L'invention concerne également des méthodes de fabrication et d'utilisation desdites compositions stabilisées à libération immédiate.
PCT/US2002/025854 2001-08-14 2002-08-14 Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees WO2003061557A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002341555A AU2002341555A1 (en) 2001-08-14 2002-08-14 Levothyroxine pharmaceutical compositions, methods of making and methods of administration

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US31211401P 2001-08-14 2001-08-14
US31227301P 2001-08-14 2001-08-14
US31211301P 2001-08-14 2001-08-14
US31218401P 2001-08-14 2001-08-14
US31248301P 2001-08-14 2001-08-14
US31228701P 2001-08-14 2001-08-14
US60/312,114 2001-08-14
US60/312,287 2001-08-14
US60/312,273 2001-08-14
US60/312,184 2001-08-14
US60/312,113 2001-08-14
US60/312,483 2001-08-15

Publications (2)

Publication Number Publication Date
WO2003061557A2 WO2003061557A2 (fr) 2003-07-31
WO2003061557A3 true WO2003061557A3 (fr) 2003-11-06

Family

ID=27617967

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/025854 WO2003061557A2 (fr) 2001-08-14 2002-08-14 Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees
PCT/US2002/025752 WO2003028624A2 (fr) 2001-08-14 2002-08-14 Compositions de levothyroxine et procedes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025752 WO2003028624A2 (fr) 2001-08-14 2002-08-14 Compositions de levothyroxine et procedes

Country Status (2)

Country Link
AU (1) AU2002341555A1 (fr)
WO (2) WO2003061557A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US11964048B2 (en) 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
EP1898926A2 (fr) 2005-05-26 2008-03-19 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
CA3064940A1 (fr) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions pour le traitement d'une fibrose
WO2019183004A1 (fr) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Formes cristallines et procédés de production de formes cristallines d'un composé
JP2022510691A (ja) 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物
DK4090313T3 (da) * 2020-01-13 2024-06-17 Amneal Complex Products Res Llc Sustained release compositions comprising liothyronine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US5955105A (en) * 1995-11-14 1999-09-21 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US5955105A (en) * 1995-11-14 1999-09-21 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US11964048B2 (en) 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine

Also Published As

Publication number Publication date
WO2003061557A2 (fr) 2003-07-31
WO2003028624A2 (fr) 2003-04-10
WO2003028624A3 (fr) 2003-11-06
AU2002341555A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
PT1412384E (pt) Formulação estável de glp-1 modificado
WO2002074247A3 (fr) Formulations pharmaceutiques a liberation prolongee
AP2001002264A0 (en) Sustained release formulations for growth hormone secretagogues.
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
IL165601A0 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
WO2003061557A3 (fr) Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees
IL150528A0 (en) Ibuprofen containing active agent preparation
MY127350A (en) Flash-melt oral dose formulations
AP2003002763A0 (en) Controlled release formulations for oral administration
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
WO2002015933A3 (fr) Combinaison
WO2003013441A3 (fr) Compositions de levothyroxine et procedes connexes
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
WO2004014318A3 (fr) Compositions de levothyroxine et procedes
ES2171110A1 (es) Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
WO1999047172A3 (fr) Compositions pharmaceutiques orales a prendre sans liquides et contenant des composes d'inclusion
MXPA03007332A (es) Composiciones de levotiroxina y metodos para elaborar la misma.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP